BEIJING, 22 September 2016–For around 90 years, antibiotics have been the go-to medicine for many illnesses. However, their systematic misuse and overuse in human medicine and food production is making bacteria increasingly resistant to their effects. Resistance is also growing to drugs commonly used to combat viruses, fungi and other parasites. This phenomenon is called antimicrobial resistance (AMR).
WHO commends Shanghai’s move to create 100% smoke-free public places Ensuring compliance and enforcement of the law essential
19 August 2016, BEIJING – The World Health Organization (WHO) applauds the Shanghai People’s Congress on its move to strengthen Shanghai’s existing tobacco control laws with respect to smoke-free public places. The Shanghai Regulations on Control of Smoking in Public Places (Amendment Draft), reviewed by the Standing Committee of the 14th Shanghai People's Congress in early August, propose making all indoor – and some outdoor – public places in Shanghai 100% smoke-free.
There is much to celebrate as China marked World Hepatitis Day this week. Large-scale immunization program has led to the current generation of Chinese children being virtually hepatitis B free. In the last year, major policy developments have paved the way for significantly improved access to treatment for both hepatitis B and C. Now, we need to translate the promise of better access to treatment into reality for all.
Up to 10 million people in China could die from chronic hepatitis by 2030 – Urgent action needed to bring an end to the ‘silent epidemic’
BEIJING, 26 July 2016 – About 10 million people living with chronic hepatitis will die mostly avoidable deaths by 2030 unless urgent action is taken to improve access to treatment. On this year’s World Hepatitis Day (28 July), WHO commends China on the progress that has been made in the last few decades in preventing the disease through wide-scale immunization. It is now time to scale up access to effective treatment for the millions of people living with chronic hepatitis who urgently need it.
- China can help stop misuse of antibiotics
- WHO commends Shanghai’s move to create 100% smoke-free public places Ensuring compliance and enforcement of the law essential
- Hepatitis treatment: Turning promise into reality
- Up to 10 million people in China could die from chronic hepatitis by 2030 – Urgent action needed to bring an end to the ‘silent epidemic’
Highlights from the country
22 March 2016
On 22 March 2016, WHO Regional Director for the Western Pacific Dr Shin Young-soo and National Health and Family Planning Commission (NHFPC) Minister Li launched the new WHO-China Country Cooperation Strategy (CCS). The CCS outlines the priorities for WHO’s work in China over the next 5 years.
14 March 2016
In 2014 WHO recommended offering pre-exposure prophylaxis (PrEP) to men who have sex with men (MSM). On the basis of further evidence of the effectiveness and acceptability of PrEP, WHO has now broadened the recommendation to include all population groups at substantial risk of HIV infection.
Offering PrEP should be a priority for populations with an HIV incidence of about 3 per 100 person-years or higher. PrEP should be an additional prevention choice in a comprehensive package of services that also includes HIV testing, counselling, male and female condoms, lubricants, ARV treatment for partners with HIV infection, voluntary medical male circumcision and harm reduction interventions for people who use drugs.
14 March 2016
WHO Technical Consultation on a comprehensive National Hepatitis Programme in China with a focus on viral hepatitis B and C treatment, Beijing, China, 21 February 2014 : meeting report
China has a heavy burden of viral hepatitis. About 90 million people are chronically infected with the hepatitis B virus and about 7 to 10 million people are estimated to be infected with the hepatitis C virus. The consequence of chronic hepatitis is substantial - liver cancer is the second leading cause of death in China in the agegroup of 35-54 years of age. Effective treatment for hepatitis B and C is available. Studies show that treatment for hepatitis B and C is cost effective, and may reduce death due to chronic hepatitis-related liver disease including liver cancer.
In view of importance of chronic hepatitis in China, a technical consultation was held on 21 February 2014 in Beijing with national stakeholders to discuss the scientific evidence, current challenges and new opportunities for scaling up hepatitis treatment in China using the public health approach.